Asacol

Phase 3Small molecule

TTillotts Pharma AG

Asacol is one of 40 small molecule programs targeting Ulcerative Colitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ulcerative ColitisActive, not recruiting

Ulcerative ColitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Velsipity

Pfizer

Phase 3

11 2

Jyseleca

Gilead

Phase 3

6 3

Skyrizi

AbbVie

Phase 3

6 4

Tremfya

Johnson & Johnson

Phase 3

2 5

Orencia

Bristol-Myers Squibb

Phase 3

1 6

Mounjaro

Eli Lilly

Phase 3

1 7

Purinethol

SStason

Phase 3

1 8

Valcyte

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 9

Adtralza

LEO Pharma

Phase 3

1 10

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ulcerative Colitis11 trials

Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis

Completed· Takeda logo

Takeda·Phase 3·NCT00151892·829 enrolled

CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

Completed· Otsuka logo

Otsuka·Phase 3·NCT00092508·1,725 enrolled

Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis

Completed·TTillotts Pharma AG·Phase 3·NCT01257386·251 enrolled

Show 8 more trials

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

Terminated·WWarner Chilcott·Phase 3·NCT01004185·39 enrolled

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

Completed·BBausch Health Americas, Inc.·Phase 3·NCT00679432·510 enrolled

Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis

Completed·WWarner Chilcott·Phase 3·NCT00073021·386 enrolled

Asacol Dosing Study for Active Ulcerative Colitis

Completed·UUniversity of Washington·Phase 4·NCT00194818·7 enrolled

TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)

Completed·TTillotts Pharma AG·Phase 3·NCT01903252·817 enrolled

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis

Completed·WWarner Chilcott·Phase 3·NCT00713310·83 enrolled

Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis

Completed·UUniversity of Chicago·Phase 3·NCT00343850·30 enrolled

Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase

Completed·TTillotts Pharma AG·Phase 3·NCT01257399·251 enrolled

Tics1 trial

Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers

Completed·WWarner Chilcott·Phase 1·NCT00751699·37 enrolled

Pediatric Patients1 trial

Safety and Compliance of Taking Mesalamine Once a Day in Pediatric Patients

Terminated·AAnnette Langseder·N/A·NCT00349388·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Asacol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Asacol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Asacol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tillotts Pharma AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTillotts Pharma AG

Asacol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ulcerative Colitis11 trials

Tics1 trial

Pediatric Patients1 trial

References

Drug Info

Quick Facts

Related News